(unaudited)
Condensed
Statements of Three Months Ended Nine Months Ended
Operations Data September 30, September 30,
------------------------- -------------------------
2024 2023 2024 2023
----------- ----------- ----------- -----------
Revenue $ -- $ -- $ -- $ --
Operating
expenses:
Research and
development 535,162 374,200 1,214,964 1,429,757
General and
administrative 1,766,010 900,089 3,470,133 2,879,036
---------- ---------- ---------- ----------
Total
operating
expenses 2,301,172 1,274,289 4,685,097 4,308,793
---------- ---------- ---------- ----------
Loss from
operations (2,301,172) (1,274,289) (4,685,097) (4,308,793)
Other Income:
Interest income 20,488 39,215 63,245 115,951
---------- ---------- ---------- ----------
Total Other
income 20,488 39,215 63,245 115,951
---------- ---------- ---------- ----------
Net loss $(2,280,684) $(1,235,074) $(4,621,852) $(4,192,842)
========== ========== ========== ==========
Net loss per share
of common stock --
basic and diluted,
as adjusted $ (2.05) $ (1.62) $ (4.95) $ (5.63)
========== ========== ========== ==========
Weighted average
shares outstanding
-- basic and
diluted, as
adjusted 1,110,317 763,750 932,872 774,586
========== ========== ========== ==========
Condensed Balance Sheet Data September 30, December 31,
2024 2023
--------------- --------------
Cash $ 2,039,819 $ 3,316,946
Total assets 2,283,249 4,165,442
Total liabilities 1,333,818 358,548
Total stockholders' equity 949,431 3,806,894
Source: Dogwood Therapeutics, Inc.
(END) Dow Jones Newswires
November 07, 2024 07:05 ET (12:05 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。